Agile Therapeutics Inc
OTC:AGRX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Agile Therapeutics Inc
F:0AL
|
9.3m EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Agile Therapeutics Inc
Glance View
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. The company is headquartered in Princeton, New Jersey and currently employs 30 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Agile Therapeutics Inc is 59.8%, which is above its 3-year median of 54%.
Over the last 3 years, Agile Therapeutics Inc’s Gross Margin has increased from -66.7% to 59.8%. During this period, it reached a low of -161.5% on Dec 31, 2021 and a high of 59.8% on Apr 2, 2024.
